REDUCE/UNDERWEIGHT: Small, disciplined initial entry at 30% of intended allocation (max 1% of NAV), hard stop at $325, no averaging down if $378 support breaks on weekly close, position capped until clean weekly close above 50 SMA or Q3 earnings de-risks procedure growth deceleration.

• Stock is 18% below its 200-day moving average with confirmed death cross, representing structural trend breakdown rather than contrarian buy signal
• MACD signal line still negative at minus 2.33; price printed lower high at $404 versus early August
• ATR compressed to 12 from 17 — does not confirm upside breakout; could signal breakdown through $378 support to $340 retest zone
• No Fed cuts in 2026 priced at 85% on Polymarket with $7.3 million volume; 30-year yield hit 19-year high; Hormuz reopening probability collapsed from 3% to 1%
• Entry multiple of 32x forward earnings is structurally squeezed with no rate relief catalyst on the calendar
• J&J received FDA De Novo authorization and intends to spend billions competing, representing credible competitive threat to surgical robotics franchise
• Revenue beat of 19% accompanied by decelerating US procedure growth, suggesting demand softness may be structural not transitory
• Oppenheimer price target of $500 requires multiple expansion contingent on earnings acceleration or rate relief that macro data does not support
• Realistic upside is $414 Bollinger upper band (~6% above entry); realistic downside is $340-$365 zone (6-13% below entry) — approximately 1-to-1 reward-to-risk, not 2-to-1 or 3-to-1
• Conservative position sizing: initial tranche 30% of intended allocation, capped at 1% of NAV until trend confirmation

→ vs aggressive: Trend exhaustion thesis is narrative not risk model — death cross is structural warning, not contrarian signal; MACD signal line remains negative at minus 2.33 and price failed at $404 versus August highs

→ vs aggressive: Buy-before-crowd logic ignores hostile macro: 85% Polymarket probability of no Fed cuts in 2026 with $7.3M volume, 30-year yield at 19-year high, and no rate relief catalyst means 32x forward P/E multiple is structurally squeezed

→ vs aggressive: Dismissing Ottava/J&J as competitive threat reveals complacency — FDA De Novo authorization signals intent to spend billions with hospital relationships and distribution advantages that represent credible franchise risk

→ vs aggressive: Reward-to-risk math of 20-to-1 payoff is misleading — honest calculation shows 1-to-1 at best (6% upside to $414 Bollinger band versus 6-13% downside to $340-$365 zone); position sizing math yields 42 basis points of NAV at risk, not 50 basis points max as claimed

→ vs aggressive: Asymmetric setup claim of 2-to-1 or 3-to-1 is contingent on multiple expansion requiring rate relief or earnings acceleration beyond consensus — neither is supported by current data

→ vs aggressive: Absent retail data being characterized as bullish is narrative spinning, not analysis — data absence is a gap that tells us nothing about positioning

BUY

• Entry at $390 with 40% initial tranche sized to 1% of NAV total exposure
• Hard stop at $325 with no discretion to widen
• Pause rule: no averaging down if $378 breaks on weekly close
• Add only above 200 SMA on weekly close OR after Q3 earnings de-risks procedure growth
• Technical: MACD crossover Aug 7, RSI 28→53, price reclaimed 50 SMA, but death cross intact and 200 SMA declining at $476
• Fundamentals: $2.80 adjusted EPS (beat by $0.30), 19% revenue growth, forward P/E 32, EPS growth 38%, PEG ~0.85
• Macro headwinds: 30-year yields at 19-year highs, 85% no-cut probability for 2026
• Realistic R/R: upside to $414 (~6%), downside $340-365 (6-13%), probability-weighted ~1.5-to-1 with 60%/$414-440 and 40%/$340-365 scenarios
• Inventory growth 21.7% YoY vs 18.5% revenue growth = 320bps gap flagged as yellow flag
• Ottava competition is a strategic risk but not near-term material; US procedure growth slowdown is more immediate concern

→ vs aggressive: Claims 20-to-1 reward-to-risk but actual R/R is ~1.5-to-1; the 20-to-1 reflects position sizing, not the trade structure itself

→ vs aggressive: Treats absence of trend followers as a buy signal rather than recognizing the stock is in base-building with confirmed death cross intact

→ vs aggressive: Dismissed Ottava as a strategic footnote; the Oppenheimer 'crowd out' thesis being published confirms competition is now an open question

→ vs aggressive: Unaddressed inventory growth of 21.7% YoY vs 18.5% revenue growth (320bps gap) is a yellow flag requiring scrutiny

→ vs conservative: 30% sizing undersizes the opportunity; 40% initial tranche is more appropriate while still being disciplined

→ vs conservative: Treating Ottava as material 12-month impact is unrealistic given hospital capital cycles and training timelines

→ vs conservative: 200 SMA at $476 is not unreachable; if trend breaks, that leg happens fast and sell-side targets cluster around $500